Abstract Number: 040 • 2023 Pediatric Rheumatology Symposium
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Over the last two decades, some children with systemic juvenile idiopathic arthritis (SJIA) have developed a severe form of interstitial lung disease (ILD) termed…Abstract Number: 376 • 2019 ACR/ARP Annual Meeting
Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been…Abstract Number: 2343 • 2019 ACR/ARP Annual Meeting
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…Abstract Number: 70 • 2018 ACR/ARHP Annual Meeting
Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients
Background/Purpose: Malondialdehyde-acetaldehyde adducts (MAA) are products of oxidative stress that modify self-proteins and stimulate potent cellular and humoral immune responses. We have previously demonstrated…Abstract Number: 526 • 2018 ACR/ARHP Annual Meeting
Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a risk factor of pneumonia in RA patients treated with biological DMARDs (bDMARDs) [1-4]. Bronchiectasis (BE) is a well-known…Abstract Number: 813 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction
Background/Purpose: Systemic sclerosis (SSc) patients frequently have upper gastrointestinal (GI) symptoms, with GI involvement being the leading cause of morbidity. Meanwhile, interstitial lung disease (ILD)…Abstract Number: 926 • 2018 ACR/ARHP Annual Meeting
Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias
Background/Purpose: The Sterile Alpha Motif Domain Containing 9 Like protein that is encoded by SAMD9L plays a role in endosome fusion, and deletions (haploinsufficiency) of…Abstract Number: 1118 • 2018 ACR/ARHP Annual Meeting
Identification of Transcriptional Regulatory Networks in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder with poor outcomes and no FDA-approved therapies. Prior work has shown gene expression patterns associated with…Abstract Number: 1123 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Background/Purpose: In patients with systemic sclerosis (SSc), plasmacytoid dendritic cells (pDCs) increase in the bronchoalveolar lavage (BAL) and lung tissues (Kafaja S, et al, JCI…Abstract Number: 1339 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
Background/Purpose: Autoimmune myositis (rheumatic muscle inflammation) associated with interstitial lung disease (ILD) and arthritis is strongly correlated with the presence of anti-histidyl tRNA synthetase (HisRS)…Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
- 1
- 2
- 3
- …
- 6
- Next Page »